Jounce Therapeutics Completed Enrollment in First Cohort of

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
36
Jounce Therapeutics Completed Enrollment in First Cohort of Phase 1 Clinical Trial with its PD-1 Inhibitor, JTX-4014

CAMBRIDGE, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced today that the company completed enrollment in the first cohort for its Phase 1 dose escalation clinical trial of JTX-4014 as monotherapy in patients with solid tumors. JTX-4014 is a fully human IgG4 monoclonal antibody designed to specifically bind to PD-1 and block its interaction with its ligands, PD-L1 and PD-L2, to augment anti-tumor T cell activity. Jounce is developing JTX-4014 for potential use in combination with its pipeline of future product candidates.

“We believe combination therapy will be the mainstay of cancer immunotherapy treatment and that PD-1 checkpoint inhibitors like JTX-4014 will be an important component of future regimens,” said Elizabeth Trehu, M.D., chief medical officer of Jounce Therapeutics. “As we continue to build and progress our immunotherapy pipeline, including macrophage and other cold tumor target treatments, we believe it is important for us to have our own PD-1 inhibitor to potentially combine with these novel agents.”

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics and to identify the recommended Phase 2 dose of JTX-4014 monotherapy in patients with advanced solid tumors. For more information on this trial, please visit https://clinicaltrials.gov (Identifier: NCT03790488).

About JTX-4014 JTX-4014 is a well-characterized fully human IgG4 monoclonal antibody designed to block binding to PD-L1 and PD-L2. Jounce is developing JTX-4014 for potential use in combination with its pipeline of future product candidates. JTX-4014 is currently in Phase 1 clinical development.

About Jounce Therapeutics Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within the human tumor microenvironment (TME) to prioritize targets, and then identifies related biomarkers designed to match the right immunotherapy to the right patient. Jounce has three development stage programs: its two clinical product candidates, JTX-2011, a monoclonal antibody that binds to and activates ICOS, and JTX-4014, a monoclonal antibody that binds to PD-1 to be used in combination with its pipeline of future product candidates, and JTX-8064, a monoclonal antibody that binds to Leukocyte Immunoglobulin Like Receptor B2 (LILRB2) that is currently in the IND-enabling phase. For more information, please visit www.jouncetx.com.

Investor Contact: Komal Joshi Jounce Therapeutics, Inc. (857) 320-2523 kjoshi@jouncetx.com

Media Contact: Gina Nugent The Yates Network (617) 460-3579 gina@theyatesnetwork.com

 

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Water Damage Coverage Has More Traps Than Homeowners Think

Updated Category News Views 29

A wet basement does not care one bit whether the water arrived dramatically or dripped in for months. That ugly distinction, though, can decide whether a homeowner has an insurance claim or a repair bill that lands with a thud. Kathy Thurmond-Edwards, an insurance expert in Memphis, Tennessee, lays out the dividing lines plainly: sudden pipe failures may be treated very...

Continue Reading
Protein Now! Gains Clinician Attention, With Caveats

Updated Category News Views 91

A Small Bottle Has Drawn a Crowd Protein powder tubs have been cluttering kitchens for years; a 3.38-fluid-ounce shot is a cleaner answer to the same daily hassle. NutraBio Labs says more than 800 physicians, nurse practitioners, and physician associates had added PROTEIN NOW! to their individual FrontrowMD patient pages as of November 2026. That earned the product a...

Continue Reading
TCL CSOT's Oxide Leap Gives LCD a Sharper Fight Ahead

Updated Category News Views 64

Fifty-one point six is the number that makes this announcement worth chewing on. TCL CSOT says it has moved ultrahigh-mobility oxide technology into mass production on an 8.6-generation line, clearing the 50 cm² V?¹ s?¹ threshold that has largely belonged to lab-talk and presentation slides. For display people, that is not decorative science. It could change the old...

Continue Reading
PAG, HOWL and PSNL Deals Face Fresh Shareholder Checks

Updated Category News Views 79

Three proposed takeovers, three very different headaches, and one familiar question that never gets old: are regular shareholders actually receiving the best available deal? On Nov. 20, 2026, investor-rights law firm Halper Sadeh LLC said it was investigating the proposed transactions involving Penske Automotive Group, Werewolf Therapeutics and Personalis for potential...

Continue Reading
North Richland Hills Bets on Its Visitor Momentum Now

Updated Category News Views 65

A crowded family attraction map is a nice problem for a Texas city to have, and North Richland Hills is trying to turn that pile of assets into a cleaner regional tourism machine. On Nov. 20, 2026, the city introduced “The Place You Never Outgrow,” its first destination-marketing campaign, built with Flat Five Marketing. This is not a stock story in the usual...

Continue Reading
Automus and Google Cloud Put Agents to Work on Oracle

Updated Category News Views 96

Oracle back offices are where shiny AI promises go to earn their keep, or get buried under a mountain of integrations. Automus Consulting’s newly announced collaboration with Google Cloud, unveiled November 20 at Oracle AI World, is aimed squarely at that messy middle. The firm wants to combine its Oracle implementation experience with Google Cloud infrastructure and...

Continue Reading
BON’s Oat Lab Bet Puts Scale and Standards in Focus

Updated Category News Views 12

Oats Meet the Industrialization Problem Oats rarely make a small-cap story more interesting, yet this one has a real business nerve running through it. Bon Natural Life has teamed with China Oat Group to establish a joint laboratory aimed at biomanufacturing high-value, oat-derived natural ingredients. The headline is not simply another research collaboration. The stated...

Continue Reading
Fire-Resistant Lubricants Offer a Quiet Value Shift

Updated Category News Views 67

Hydraulic fluid is not the sort of product that gets anyone pounding the table, and that is precisely why this little industrial pocket deserves a hard look. The fire-resistant lubricants market is estimated at $2.35 billion in 2026 and projected to reach $2.83 billion by 2031, implying a 3.74% compound annual growth rate. That is not a rocket ship. It is a slow-moving,...

Continue Reading
Cloud Security’s $26.8 Billion Test Is All About Execution

Updated Category News Views 65

A cloud dashboard that spits out ten thousand alerts is not protection; it is an expensive way to make a security team miserable. That frustration sits right in the middle of Frost & Sullivan’s projection that global cloud security revenue will climb from $8.4 billion in 2025 to $26.8 billion by 2031, a 21.4% compound annual growth rate. The number is hefty, no...

Continue Reading
Union Pacific Faces $98.8 Million Arbitration Tab

Updated Category News Views 75

A Missed Schedule Promise Got Very Expensive Railroad labor disputes can look like paperwork until the bill lands with a thud. Union Pacific is facing an estimated $98.8 million arbitration payout after a Special Board of Adjustments found that the carrier failed to implement a negotiated scheduling benefit for locomotive engineers. That is not loose change, and it is the...

Continue Reading

Top 5 Most Recently Viewed Articles

Vidrio Financial and Investcorp-Tages Enhance Partnership for Investment Solutions

Updated Category News Views 109

Vidrio Financial and Investcorp-Tages Expand Their Partnership Vidrio Financial, an AI-driven software solution designed for global institutional allocators, has announced an expanded partnership with Investcorp-Tages to enhance coverage in private market investment initiatives. This collaboration aims to provide advanced monitoring and data transparency in the...

Continue Reading
Linkers Industries Limited Schedules Initial IPO for Nasdaq Launch

Updated Category News Views 115

Linkers Industries Limited Commences Initial Public Offering Linkers Industries Limited (Nasdaq: LNKS), a prominent manufacturer and supplier of wire and cable harnesses, has officially announced the pricing of its initial public offering (IPO). This exciting development follows a well-organized plan aimed at expanding its operations and reach within the industry. Details...

Continue Reading
OutKick Reports Impressive Growth in Visitor Engagement Metrics

Updated Category News Views 187

OutKick's Impressive Q2 Performance In 2025, OutKick, a prominent multimedia sports platform, showcased remarkable growth from the first to the second quarter. The latest metrics reveal that average unique visitors across desktop and mobile platforms increased by 26%, totaling 6.2 million. Alongside this, the platform recorded a substantial rise in total views, soaring by...

Continue Reading
Celebrating David R. Walt's Achievement with Technology Medal

Updated Category News Views 274

David R. Walt Honored with National Medal of Technology and Innovation BILLERICA, Mass.-- Quanterix Corporation (NASDAQ: QTRX), a leader in ultrasensitive biomarker detection, proudly announces that David R. Walt has received the prestigious National Medal of Technology and Innovation. This honor is awarded by the President of the United States, celebrating individuals...

Continue Reading
HALO AirFinance Completes Successful Loan Transactions

Updated Category News Views 262

HALO AirFinance Finalizes Its Eighth Loan HALO AirFinance, a collaborative effort between GA Telesis and Tokyo Century Corporation, has successfully closed its eighth and final loan for Crestone Air Partners. This significant transaction involved the acquisition of a CFM56-7B engine, which has been leased to a European carrier. The completion of this deal highlights the...

Continue Reading